文献速递乳腺癌

内分泌治疗耐药乳腺癌中反复出现的超活性ESR1融合蛋白

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究通过多模态测序在三个乳腺癌患者队列中识别ESR1基因组结构重排,发现88例ESR1重排,直接确认9种ESR1融合蛋白,所有融合均缺失配体结合域,体外实验显示融合蛋白不依赖配体且活性增强,提示ESR1融合是内分泌治疗耐药的 recurrent 驱动因素且对ER靶向治疗不敏感。

要点

  • ESR1融合在ER阳性转移性乳腺癌中富集,与ESR1错义突变共存提示多克隆耐药。
  • 所有融合断点位于ESR1内含子6附近,缺失完整配体结合域。
  • ESR1融合蛋白不依赖配体且活性增强,对ER靶向治疗不敏感。

核心结论

  • N端ESR1融合(涉及外显子6-7)是内分泌治疗耐药的反复驱动因素,且对ER靶向治疗不敏感。

研究设计与样本

  • 多模态测序研究:6对原发-转移肿瘤和51例转移灶行mate-pair和/或RNAseq;9542例实体瘤(5216例转移)行287-395个癌症相关基因高覆盖(>500×)基因组分析;254例ctDNA样本行62个癌症相关基因超高覆盖(>5000×)基因组分析。

主要发现

  • 在83例独特患者中识别88例ESR1重排,直接确认9种ESR1融合蛋白(其中2种通过免疫印迹)。
  • ESR1重排高度富集于ER阳性转移性疾病,并与已知ESR1错义变异共存,提示多克隆耐药。
  • 所有融合均源于ESR1内含子6内或附近的断点,因此缺乏完整配体结合域。
  • 三种融合的体外表征显示配体非依赖性和依赖于3'伙伴基因的超活性。
  • ESR1融合在转移性实体乳腺癌中的下限估计至少为1%,在ctDNA中的患病率至少富集10倍。

关键数值与推荐

  • ESR1融合在转移性实体乳腺癌中下限估计至少1%。
  • ESR1融合在ctDNA中患病率至少富集10倍。

临床怎么用

  • 对于ER阳性转移性乳腺癌内分泌治疗耐药患者,应考虑检测ESR1融合以指导治疗决策。
  • ESR1融合阳性患者可能对ER靶向治疗不敏感,需探索其他治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Estrogen receptor-positive (ER-positive) metastatic breast cancer is often intractable due to endocrine therapy resistance. Although ESR1 promoter switching events have been associated with endocrine-therapy resistance, recurrent ESR1 fusion proteins have yet to be identified in advanced breast cancer. PATIENTS AND METHODS: To identify genomic structural rearrangements (REs) including gene fusions in acquired resistance, we undertook a multimodal sequencing effort in three breast cancer patient cohorts: (i) mate-pair and/or RNAseq in 6 patient-matched primary-metastatic tumors and 51 metastases, (ii) high coverage (>500×) comprehensive genomic profiling of 287-395 cancer-related genes across 9542 solid tumors (5216 from metastatic disease), and (iii) ultra-high coverage (>5000×) genomic profiling of 62 cancer-related genes in 254 ctDNA samples. In addition to traditional gene fusion detection methods (i.e. discordant reads, split reads), ESR1 REs were detected from targeted sequencing data by applying a novel algorithm (copyshift) that identifies major copy number shifts at rearrangement hotspots. RESULTS: We identify 88 ESR1 REs across 83 unique patients with direct confirmation of 9 ESR1 fusion proteins (including 2 via immunoblot). ESR1 REs are highly enriched in ER-positive, metastatic disease and co-occur with known ESR1 missense alterations, suggestive of polyclonal resistance. Importantly, all fusions result from a breakpoint in or near ESR1 intron 6 and therefore lack an intact ligand binding domain (LBD). In vitro characterization of three fusions reveals ligand-independence and hyperactivity dependent upon the 3' partner gene. Our lower-bound estimate of ESR1 fusions is at least 1% of metastatic solid breast cancers, the prevalence in ctDNA is at least 10× enriched. We postulate this enrichment may represent secondary resistance to more aggressive endocrine therapies applied to patients with ESR1 LBD missense alterations. CONCLUSIONS: Collectively, these data indicate that N-terminal ESR1 fusions involving exons 6-7 are a recurrent driver of endocrine therapy resistance and are impervious to ER-targeted therapies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hartmaier RJ, Trabucco SE, Priedigkeit N, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol. 2018. PMID: 29360925. doi:10.1093/annonc/mdy025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。